Objectives. The aim was to establish the prevalence and severity of faecal incontinence (FI) in SSc, its association with other intestinal manifestations and potential predictors of FI, and its impact on quality of life.
Introduction
SSc is an autoimmune disease of unknown aetiology characterized by vasculopathy, immunological dysregulation, excessive collagen deposition and fibrosis affecting both skin and visceral organs [1, 2] . The gastrointestinal (GI) tract is involved in 7590% of patients [25] . Despite numerous improvements in the care provided to patients in the last decades, SSc-related mortality attributable to internal organ involvement remains high [6, 7] . Although large gaps in our understanding of the underlying pathophysiological mechanisms of GI disease in SSc persist, both myogenic and neurogenic abnormalities are thought to have contributory roles [811] . The entirety of the GI tract can be involved in SSc, including the anorectal portion [1214] . Anorectal dysfunction is commonly associated with significant distress and poor health-related quality of life (HRQoL) [2, 8, 15] .
Faecal incontinence (FI) is a manifestation of anorectal dysfunction. Studies have reported the prevalence of FI in SSc to range between 20 and 39% [2, 8, 1618] . However, these studies have several limitations, including small, single-centre samples and use of ad hoc outcome measures. In addition, the severity, predictors and impact on HRQoL of FI in SSc remain largely unknown.
The primary objective of this study was to identify the prevalence and severity of FI in a large multicentre SSc cohort using validated questionnaires. Secondary objectives were to study the association between FI and bowel dysfunction and other potential predictors of FI, and to determine the impact of FI on HRQoL.
Methods

Subjects
Subjects were prospectively enrolled at seven sites participating in the Canadian Scleroderma Research Group (CSRG) cohort study. More than 98% of the subjects in the CSRG cohort meet the 2013 ACR/EULAR classification criteria for SSc [19] . Inability of the subjects to speak, understand or read English or French, to complete selfreport questionnaires, or the presence of previous major intestinal surgeries potentially impacting on FI (e.g. colostomy) were exclusion criteria.
Ethical considerations
The study was approved by the Université de Sherbrooke Ethics Research Board and all other participating study sites. All subjects provided written informed consent prior to entering the study.
Study variables
Data were collected between March 2014 and May 2015. All demographic and most disease-specific characteristics were collected using the CSRG standardized data collection protocol. Small intestinal bacterial overgrowth (SIBO) was considered present if a study physician reported that the subject was currently or was ever treated with antibiotics for bacterial overgrowth. Study physicians completed a complementary data sheet to record exposure to various GI drugs and antibiotics for SIBO. Medications included in the study were defined as either those treating constipation, including fibres, stool softeners and stimulant laxatives, or those associated with an elevated risk of constipation, including iron supplements, calcium and loperamide. Exposure to different prokinetic agents, such as domperidone, metoclopramide, octreotide or cisapride, was recorded as well as any gastroprotective drugs, including proton-pump inhibitors and antacids. Subjects were asked to complete an additional questionnaire relating to obstetrical and surgical history. Vaginal deliveries were noted to present local complications if they were associated with third degree or more perineal tear or if there was a need for either forceps or episiotomy.
Measures of FI and bowel symptoms
The JorgeWexner score (JWS) was used to measure FI. It ranges from 0 to 20, with 20 being most severe [20] . The score is calculated based on different degrees of FI: gas incontinence, liquid incontinence, solid incontinence, the need to wear a pad and lifestyle alteration. In agreement with previously reported studies, a score of 55 was used to identify the presence of FI and 510 to define moderateto-severe FI [21, 22] . The Rome III criteria were used to define constipation [23] . Criteria include straining, incomplete evacuation, anorectal obstruction, manual manoeuvre and <3 defecations per week. Subjects with 52 criteria were defined as having constipation. Consistency of stool was assessed through the Bristol stool scale (BSS), a visual scale measuring stools from 1, being hardest, to 7, being completely liquid stool [24] . The HRQoL was evaluated using the Faecal Incontinence Quality-of-Life scale (FIQoL). This questionnaire consists of 29 items evaluating four different domains: lifestyle, coping/behaviour, depression/self-perception and embarrassment [25] . A score ranging from 1 to 5 is obtained for each domain, with 1 indicating lower quality of life.
Serology
Serum was collected at the baseline registry visit and sent to a central laboratory at the University of Calgary, where samples were aliquotted and stored at À80 C until needed. Anti-centromere (CENP-A and CENP-B; ACA), anti-topo I (ATA) and anti-RNA polymerase III (RP11 and RP155; ARNAP) antibodies were detected by Euroline SSc profile line immunoassay (Euroimmun, Luebeck, Germany) according to the manufacturer's instructions. With the intent of optimizing specificity, antibodies were reported as absent (negative, equivocal and low titres) or present (moderate and high titres).
Statistical analysis
Descriptive statistics were used to summarize baseline characteristics. Continuous normally distributed variables were presented with the mean (S.D.), and non-normal variables with the median and interquartile range (IQR; 2575th percentiles 
Results
Characteristics of study sample
This study included 298 SSc subjects from seven sites. The mean age was 59.4 (12.1) years, 87.9% were women, median disease duration was 10.5 years (IQR: 6.618.1), and 62.7% were classified as lcSSc. ACA were present in 40.9% of the subjects, whereas ATA and ARNAP were found in 15.5 and 13.5%, respectively. Sixty-one subjects (20.9%) were taking prokinetic agents, and 38 (13.4%) had been treated with antibiotics for SIBO since disease onset. Median BSS was 4.0 (IQR: 3.04.0), suggesting that most patients had well-formed stools, and 111 (38.8%) subjects met the Rome III criteria for constipation.
Presence and severity of FI Eighty-one (27.2%) subjects had FI, defined as a JWS 55. Among these, 37 (12.4%) had mild (JWS 59) and 44 (14.8%) moderate-to-severe FI (JWS 510).
Predictors of FI
Subjects with FI (JWS 55; FI + ) were compared with those without FI (JWS <5; FI À ; Table 1 ). The FI + subjects were older (62.4 vs 58.3 years, P = 0.01) and more likely to have longer disease duration (median duration 12.8 vs 9.9 years, P = 0.01). Women tended to have FI more than men (93.4 vs 85.7%, P = 0.056). The FI + subjects were more likely to be positive for ACA compared with FI À subjects (56.2 vs 34.6%, P = 0.002). There were no significant differences between FI + and FI À subjects as far as disease subsets, ATA or ARNAP were concerned. Likewise, there were no significant differences between modified Rodnan skin scores and rates of interstitial lung disease, pulmonary hypertension and digital ulcers between both groups. Also, FI + subjects were significantly more likely to have overlap with SS compared with FI À subjects (30.9 vs 19.5%, P = 0.038).
A history of vaginal delivery was reported in 72.8% of FI + subjects compared with 56.7% of FI À subjects. Complicated vaginal deliveries were significantly more frequent in FI + compared with FI À subjects (67.9 vs 43.8%, P < 0.001). Few subjects had a history of haemorrhoidectomy or anal surgery, although other pelvic floor surgery was more common in FI + compared with FI À subjects (6.3 vs 0.9%, P = 0.017). Urinary incontinence was common, but was significantly more common in FI + compared with FI À subjects (54.4 vs 24.2%, P < 0.001 .9%, respectively; P < 0.001). There was no significant difference in the need for manual disimpaction or defecation <3 times per week between the two groups.
The following four variables emerged as independent predictors of FI in multivariate logistic regression analyses (Table 2) 
Impact of FI on HRQoL
HRQoL was measured with the FIQoL. Severity of FI was associated with worse FIQoL scores (Fig. 1) . Indeed, there were strong negative correlations between JWS and the four domains of the FIQoL: lifestyle [Spearman correlation (r s ) = À0.669, P < 0.001], coping/behaviour (r s = À0.702, P < 0.001), depression/self-perception (r s = À0.600 P < 0.001) and embarrassment (r s = À0.687, P < 0.001).
Discussion
In this cohort of nearly 300 SSc subjects, more than onequarter experienced FI; half had moderate-to-severe disease. Loose stools, constipation, SIBO and urinary incontinence were strongly and independently associated with FI. FI had a strong negative impact on HRQoL.
The prevalence of FI in the general population ranges between 5 and 7% [21, 26] . In SSc, it was previously reported to range between 20 and 39% [2, 8, 16, 17] . Our results, derived from a large, multicentre cohort using validated instruments, are consistent with these estimates. Moreover, our results extend these findings by estimating severity and independent predictors of FI in SSc. Other studies have already shown the influence of FI on HRQoL www.rheumatology.oxfordjournals.org in SSc [2, 15, 17, 18] . Our study confirms these findings using a validated instrument and identifies specific domains of HRQoL involved. Not surprisingly, FI was strongly associated with embarrassment and negative impact on lifestyle, coping and self-perception.
Independent associations between loose stools, SIBO and FI in SSc are novel. Ng et al. [27] recently reported an association between loose stools and FI in a communitybased general adult population. We hypothesize that loose or watery stools probably compound anal sphincter dysfunction in SSc. Improving stool consistency has previously been suggested to prevent FI [28] . Additional studies will be needed to determine whether this approach is effective in SSc.
In this study, more than one-third of subjects were found to have constipation according to the Rome III criteria. Interestingly, constipation was also strongly associated with FI. Indeed, constipation is a well-established risk factor for FI in non-SSc populations [29, 30] . Three main mechanisms are thought to explain this relationship: faecal impaction, rectal evacuatory dysfunction and pelvic floor weakness [31] . Our data are consistent with these mechanisms, with straining, incomplete evacuation and anorectal obstruction reported more commonly in FI + compared with FI À subjects. Interestingly, we found somewhat discrepant results pertaining to constipation. Constipation using the Rome III criteria was positively associated with FI, whereas hard stools assessed by the BSS did not influence FI. We hypothesize that this may be related to SIBO, which is common in SSc and which can present as alternating constipation and diarrhoea. Some subjects in this study reported both constipation (using the Rome III questionnaire) and loose stools (with the visual BSS). However, the BSS was only recorded at one point in time, and subjects were specifically instructed to record the general appearance of their stool in the last month, whereas symptoms of constipation were queried as at least one out of four bowel movements but without relating to a specific time period. Thus, the BSS may not have captured temporal variations in stool consistency in particular in subjects with SIBO. An alternative explanation is that the scales may not be capturing the same information. In any case, in this cross-sectional study, constipation does not appear to be synonymous with hard stool.
Urinary incontinence has been associated with FI in non-SSc populations and was therefore included as a potential covariate of interest in our study [27, 32] . Surprisingly, we found that 32% of our SSc subjects reported urinary incontinence. A recent study in SSc also reported the presence of urinary incontinence in 30% of their sample [17] . Although pelvic floor dysfunction is thought to contribute to urinary incontinence, it remained a significant predictor of FI in our study after adjusting for previous obstetrical events and pelvic floor surgery. Other abnormalities present in SSc, such as sphincter dysfunction and neuropathy, may therefore also contribute to urinary incontinence in this disease. Further studies investigating this fairly new and common symptom in SSc are required.
Our study has considerable strengths, including the large, multicentre sample, which contributes to generalizability and robustness of results. We used validated instruments, including the JWS, which is easy to use, can be rapidly completed by the subject, correlates well with physician clinical impression of FI severity and appears to be sensitive to change [33, 34] . Furthermore, when compared with other FI assessment tools, including the Rothenberg scale [35] , the Vaizey scale [34] and the Faecal Incontinence Severity Index [36] , the JWS has been reported to be the most precise and comprehensive [37] . In particular, the University of California at Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0 (UCLA SCTC GIT 2.0) [38] was Excluding haemorrhoidectomy and anal fissure surgery because these were not related to faecal incontinence, with P < 0.01 in univariate analyses. SIBO: small intestinal bacterial overgrowth.
www.rheumatology.oxfordjournals.org designed and validated to assess the presence and impact of GI symptoms in SSc [39, 40] . However, faecal soilage is assessed with only a single question. The rapid assessment faecal incontinence score is a new FI scoring system that has the advantage of being quick and easy to perform, and it has shown significant correlation with the JWS [41] . Even if it could be a promising clinical tool, this test is limited by the fact that it does not take into account faecal urgency or type of incontinence (gas, liquid or solid) [41] . In the present study, we also used the BSS, which is a widely used 7-point visual scale to assess stool consistency [24, 42] . This scale was correlated with complete gut transit time in healthy control subjects and in patients with GI disorders [43, 44] . The FIQoL was developed and validated by the American Society of Colon and Rectal Surgeons specifically to assess FI-related HRQoL [25, 32] . Considering that a good proportion of our study population was also French speaking, we had the opportunity to use, when needed, the validated French version of the FIQoL [45] .
Our study is not without limitations. There is no validated threshold to define FI with the JWS. We adopted the cut-off of 55 based on a study where this threshold was proposed to eliminate situations where gas incontinence alone has little effect on quality of life [21] . Moreover, although a correlation between a score >9 and major deterioration in HRQoL has been reported [22] , thereby justifying our second threshold defining moderate-to-severe FI (JWS 510), this too remains to be validated formally. FI and bowel symptoms were self-reported and, when performed, results of objective testing, such as stool studies, anal endosongraphy or anal manometry [9] , were not collected. Nonetheless, because these are symptoms, the subjective perception of the subject is inherent in their assessments [46] . Finally, our cohort consisted largely of SSc subjects with established disease. Thus, it was not 
Conclusions
In conclusion, in this comprehensive and systematic study of FI in SSc, we found robust evidence that FI is common and often severe in SSc and is associated with impaired HRQoL. Bowel symptoms commonly reported in SSc, including loose stools, SIBO and constipation, were strongly and independently associated with FI. Clinicians should be aware that common bowel manifestations of SSc are associated with more severe FI. Other than specifically targeting anorectal dysfunction (e.g. physical therapy or neurostimulation), prompt recognition and systematic management of these have the potential to lead to improvements in FI and quality of life in SSc.
